PROCEPT BioRobotics to Report Third Quarter 2022 Financial Results on November 3, 2022
12 10월 2022 - 9:00PM
PROCEPT® BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a
surgical robotics company focused on advancing patient care by
developing transformative solutions in urology, today announced it
will report financial results for the third quarter of 2022 after
market close on Thursday, November 3, 2022. The Company’s
management will host a corresponding conference call beginning at
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do
so by following one of the below links:
- Webcast link for interested listeners:
- https://edge.media-server.com/mmc/p/ivt2yxvx
- Dial-in registration for sell-side research analysts:
-
https://register.vevent.com/register/BI27c09ae00d714d73950186b824915f76
Live audio of the webcast will be available on the “Investors”
section of the Company’s website at:
https://ir.procept-biorobotics.com.
An archived recording will be available on the “Investors”
section of the Company’s website at:
https://ir.procept-biorobotics.com. The webcasts will be available
for replay for at least 90 days after the event.
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT BioRobotics designed Aquablation
therapy to deliver effective, safe and durable outcomes for males
suffering from lower urinary tract symptoms, or LUTS, due to BPH
that are independent of prostate size and shape or surgeon
experience. PROCEPT BioRobotics has developed a significant and
growing body of clinical evidence, which includes nine clinical
studies and over 100 peer-reviewed publications, supporting the
benefits and clinical advantages of Aquablation therapy.
Investor Contact:Matt Bacso, CFAVP, Investor
Relations and Business
Operationsm.bacso@PROCEPT-BioRobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024